GlassScriptPhysician profile
Corinna Jay Kirkpatrick
NPI 1609145309
$2,159.98
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $482 · 2022: $754 · 2023: $901 · 2024: $22.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $923.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $404.82 | 2021-2023 | Ozempic, Rybelsus, Saxenda |
| Lilly USA, LLC | $360.04 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $215.72 | 2021-2023 | Prolia, Evenity, Otezla |
| Glaxosmithkline, LLC. | $200.53 | 2022-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $117.75 | 2021-2023 | |
| Abbott Laboratories | $104.50 | 2022-2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $100.08 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $90.98 | 2022-2024 | |
| Abbvie INC. | $76.57 | 2022-2023 | |
| Exact Sciences Corporation | $68.33 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $41.77 | 2021-2022 | |
| Biofire Diagnostics, LLC | $37.14 | 2021 | |
| Insulet Corporation | $35.29 | 2023 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $34.73 | 2021 | |
| Xeris Pharmaceuticals, INC. | $34.59 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $30.47 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.03 | 2022-2023 | Jardiance, Tradjenta |
| Sunovion Pharmaceuticals INC. | $26.33 | 2022 | |
| Mylan Specialty L.P. | $25.91 | 2022 | |
| Astellas Pharma US INC | $24.44 | 2023 | Veozah |
| Sumitomo Pharma America, INC. | $20.98 | 2023 | Gemtesa |
| Lifescan, INC. | $17.31 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $17.25 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.12 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $16.01 | 2023 | |
| Eisai INC. | $13.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corinna Kirkpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.